OptimizeRx Corp. (NASDAQ:OPRX) Given Consensus Recommendation of “Moderate Buy” by Analysts

OptimizeRx Corp. (NASDAQ:OPRX) has been assigned a consensus rating of “Moderate Buy” from the nine research firms that are covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, two have given a hold recommendation and six have given a buy recommendation to the company. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $21.00.

Several brokerages have recently commented on OPRX. Citizens Jmp boosted their price objective on OptimizeRx from $23.00 to $24.00 and gave the stock a “market outperform” rating in a report on Friday, November 7th. Weiss Ratings reissued a “sell (d+)” rating on shares of OptimizeRx in a research note on Monday, December 22nd. Citigroup reissued an “outperform” rating on shares of OptimizeRx in a report on Friday, October 10th. Zacks Research downgraded shares of OptimizeRx from a “strong-buy” rating to a “hold” rating in a report on Monday, December 15th. Finally, Stephens cut their target price on shares of OptimizeRx from $20.00 to $17.00 and set an “equal weight” rating for the company in a research report on Monday, November 17th.

OptimizeRx Trading Up 3.3%

Shares of OPRX stock opened at $10.89 on Friday. The company has a market capitalization of $202.99 million, a PE ratio of 26.35 and a beta of 1.18. OptimizeRx has a 52-week low of $3.99 and a 52-week high of $22.25. The business’s fifty day moving average is $12.66 and its 200 day moving average is $15.60. The company has a debt-to-equity ratio of 0.20, a quick ratio of 3.05 and a current ratio of 3.05.

OptimizeRx (NASDAQ:OPRX) last posted its earnings results on Thursday, November 6th. The company reported $0.20 EPS for the quarter, topping the consensus estimate of $0.03 by $0.17. The business had revenue of $26.07 million during the quarter, compared to analysts’ expectations of $23.83 million. OptimizeRx had a return on equity of 6.37% and a net margin of 0.03%. On average, equities research analysts anticipate that OptimizeRx will post -0.33 EPS for the current fiscal year.

Hedge Funds Weigh In On OptimizeRx

Several institutional investors have recently modified their holdings of OPRX. Nisa Investment Advisors LLC lifted its position in OptimizeRx by 600.0% in the 2nd quarter. Nisa Investment Advisors LLC now owns 2,121 shares of the company’s stock worth $29,000 after buying an additional 1,818 shares during the last quarter. Parkman Healthcare Partners LLC raised its stake in shares of OptimizeRx by 0.4% during the third quarter. Parkman Healthcare Partners LLC now owns 509,611 shares of the company’s stock worth $10,447,000 after acquiring an additional 2,188 shares in the last quarter. BNP Paribas Financial Markets lifted its holdings in shares of OptimizeRx by 119.2% in the 2nd quarter. BNP Paribas Financial Markets now owns 4,074 shares of the company’s stock worth $55,000 after acquiring an additional 2,215 shares during the last quarter. Harbor Capital Advisors Inc. boosted its stake in shares of OptimizeRx by 12.2% in the 4th quarter. Harbor Capital Advisors Inc. now owns 24,876 shares of the company’s stock valued at $305,000 after purchasing an additional 2,708 shares in the last quarter. Finally, Quantbot Technologies LP purchased a new stake in shares of OptimizeRx in the 2nd quarter valued at $44,000. 76.47% of the stock is currently owned by institutional investors.

OptimizeRx Company Profile

OptimizeRx, Inc is a healthcare technology company that operates a digital health network designed to facilitate communication between pharmaceutical manufacturers, payers and healthcare providers. Through its cloud-based platform, OptimizeRx delivers targeted digital interventions—such as patient savings messages, clinical content and product information—directly into electronic health record (EHR) workflows at the point of care. By integrating with leading EHR systems, the company helps life sciences organizations optimize brand engagement, improve patient adherence and support informed prescribing decisions.

The company’s core offerings include digital prescription benefit notifications, co-pay assistance alerts and real-time clinical messaging tailored to specific patient populations.